Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-05-13 5:34 pm Unchanged | 2024-03-25 | 13G | Q32 Bio Inc. QTTB | ARCH Venture Fund VIII L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2024-02-14 3:17 pm Sale | 2023-10-12 | 13G | Scholar Rock Holding Corporation SRRK | ARCH Venture Fund VIII L.P. | 0 0.000% | -2,637,617 (Position Closed) | Filing History |
| 2022-09-20 4:57 pm Purchase | 2022-09-13 | 13D | CODIAK BIOSCIENCES INC CDAKQ | ARCH Venture Fund VIII L.P. | 8,854,098 24.700% | 5,000,000 (+129.73%) | Filing History |
| 2022-02-08 3:04 pm Sale | 2021-12-31 | 13G | Denali Therapeutics Inc. DNLI | ARCH Venture Fund VIII L.P. | 0 0.000% | -10,735,948 (Position Closed) | Filing History |
| 2021-02-04 5:11 pm Purchase | 2020-12-31 | 13G | CODIAK BIOSCIENCES INC CDAKQ | ARCH Venture Fund VIII L.P. | 3,854,098 20.500% | 3,854,098 (New Position) | Filing History |
| 2021-02-02 5:04 pm Purchase | 2020-12-31 | 13G | Metacrine, Inc. MTCR | ARCH Venture Fund VIII L.P. | 2,940,503 11.300% | 2,940,503 (New Position) | Filing History |
| 2021-02-02 5:04 pm Purchase | 2020-12-31 | 13G | Denali Therapeutics Inc. DNLI | ARCH Venture Fund VIII L.P. | 10,735,948 9.000% | 37,339 (+0.35%) | Filing History |
| 2020-02-13 4:53 pm Unchanged | 2019-12-31 | 13G | Scholar Rock Holding Corporation SRRK | ARCH Venture Fund VIII L.P. | 2,637,617 8.900% | 0 (Unchanged) | Filing History |
| 2020-02-13 4:52 pm Sale | 2019-12-31 | 13G | Denali Therapeutics Inc. DNLI | ARCH Venture Fund VIII L.P. | 10,698,609 11.100% | -370,140 (-3.34%) | Filing History |
| 2020-02-13 4:51 pm Sale | 2019-12-31 | 13G | Homology Medicines, Inc. FIXX | ARCH Venture Fund VIII L.P. | 320,551 13.100% | -16,599 (-4.92%) | Filing History |